一种新的IRAK4抑制剂DW18134 改善腹膜炎和炎症性肠病
Yuqing Huang1,2, Yi Ning3,4, Zhiwei Chen4,5
1Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.
Molecules (Basel, Switzerland)
|April 27, 2024
概括
一种新型的小分子抑制剂,DW18134,有效地向IRAK4 (介素-1受体关联激酶4) 以减少炎症. 这种化合物对治疗自身免疫性疾病,如腹膜炎和炎症性肠病 (IBD) 是有前途的.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学 是一个学科.
- 药物发现 药物发现 药物发现
背景情况:
- 介素-1受体相关激酶4 (IRAK4) 是NF-κB炎症信号通路中的关键调解剂.
- IRAK4抑制剂是自身免疫性疾病的潜在治疗药物,但没有一个是FDA批准的.
- 开发新的IRAK4抑制剂对于推进自身免疫性疾病治疗至关重要.
研究的目的:
- 为了识别和表征一种新的小分子IRAK4激酶抑制剂.
- 在炎症性疾病的临床前模型中评估已识别的抑制剂的治疗潜力.
- 阐明新型抑制剂的作用机制.
主要方法:
- 在体外激酶抑制试验测试以确定IC50值.
- 基于细胞的测定测量细胞因子分泌 (TNF-α,IL-6) 和蛋白质酸化.
- 在体内研究使用脂聚糖 (LPS) 诱导的周周炎和硫酸 (DSS) 诱导的结肠炎模型.
- 评估疾病活动,炎症标志物和肠道屏障功能.
主要成果:
- 一种新的IRAK4抑制剂,DW18134,被确定为IC50的11.2nM.
- 在体外,DW18134剂量依赖地抑制了IRAK4/IKK酸化和降低了TNF-α/IL-6分泌.
- 在体内,DW18134减弱了LPS诱导的腹膜炎和DSS诱导的结肠炎,减少了疾病活性和炎症标志物.
- DW18134通过调高紧密结基因表达来改善肠道屏障功能.
结论:
- DW18134是一种强效的小分子IRAK4抑制剂.
- DW18134在炎症性疾病,如腹膜炎和炎症性肠病 (IBD) 中具有显著的治疗潜力.
- 这些发现支持DW18134作为治疗IRAK4介导的炎症性疾病的有希望的候选药物.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
160
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
160
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
134
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
134
Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs for Treatment of Diarrhea-Predominant IBS
161
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
161


